Session

IBD (Posters)

REAL-TIME USE OF ARTIFICIAL INTELLIGENCE DURING COLONOSCOPY PREDICTS RELAPSE OF ULCERATIVE COLITIS: A PROSPECTIVE STUDY
REAL-TIME USE OF ARTIFICIAL INTELLIGENCE DURING COLONOSCOPY PREDICTS RELAPSE OF ULCERATIVE COLITIS: A PROSPECTIVE STUDY

INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE: TREATMENT AND OUTCOMES
INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE: TREATMENT AND OUTCOMES

IMPROVEMENT IN PATIENT ACTIVATION MEASURE (PAM) IS SEEN FOLLOWING A FOCUSED FRAMEWORK OF EDUCATION IN A NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE COHORT
IMPROVEMENT IN PATIENT ACTIVATION MEASURE (PAM) IS SEEN FOLLOWING A FOCUSED FRAMEWORK OF EDUCATION IN A NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE COHORT

SERIOUS ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: WHO IS MOST AT RISK?
SERIOUS ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: WHO IS MOST AT RISK?

EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU.
EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU.

INCIDENCE AND RISK FACTORS FOR NEOPLASIA IN INFLAMMATORY BOWEL DISEASE
INCIDENCE AND RISK FACTORS FOR NEOPLASIA IN INFLAMMATORY BOWEL DISEASE

CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS
CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS

CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY
CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY

ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING
ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING

RATES OF TREATMENT FAILURE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FIRST-LINE ADVANCED TREATMENTS
RATES OF TREATMENT FAILURE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FIRST-LINE ADVANCED TREATMENTS

CORRELATION OF MUCOSAL MICROBIAL DIVERSITY WITH MARKER OF INFLAMMATION IN CROHN'S DISEASE
CORRELATION OF MUCOSAL MICROBIAL DIVERSITY WITH MARKER OF INFLAMMATION IN CROHN'S DISEASE

INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU
INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THE PATIENTS AND THEIR FAMILIES IN DIFFERENT WAYS DEPENDING ON THE AGE AT DIAGNOSIS
PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THE PATIENTS AND THEIR FAMILIES IN DIFFERENT WAYS DEPENDING ON THE AGE AT DIAGNOSIS

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

ASSOCIATION BETWEEN DAILY INTAKE OF ADDED SUGAR AND DISEASE ACTIVITY OR QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ASSOCIATION BETWEEN DAILY INTAKE OF ADDED SUGAR AND DISEASE ACTIVITY OR QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB - A POST HOC ANALYSIS OF SELECTION
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB - A POST HOC ANALYSIS OF SELECTION

Item 121 - 140 / 568
1 2 3 4 5 6
7
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29